[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Nymo S., Coutinho S., Eknes P., Vestbostad I., Rehfeld J., Truby H., Kulseng B., Martins C
DPP-IV inhibitors have shown promise in modulating the immune response, particularly by enhancing T-cell function
A meta-analysis [74] including the ELIXA [66], LEADER [44], SUSTAIN-6 [67], EXSCEL [68], REWIND [70], and AMPLITUDE-O [51] studies found that GLP-1RAs were associated with better renal outcomes: a 30% or 40% or more decrease in glomerular filtration rate, need for renal replacement therapy, end-stage renal failure, or death from kidney disease by 21%
Oral administration follows a ramping protocol: 250 micrograms daily for the first three weeks, increasing to 500 micrograms for maintenance
Fast-Acting Supplement